CNS-pen. GABAA-_5 neg. allo. mod. (NAM)

Ph. II for Down syndrome (240 mg BID)

from 56k cmpd competition binding HTS

Sci. Rep., Apr. 8, 2021

Roche Innovation Center, Basel, CH

basmisanil

The Roche GABAA-α5 selective negative allosteric modulator (NAM), basmisanil, is a Ph. II candidate for intellectual disability in Down syndrome. GABAA receptors assemble as pentamers of subunits, and non- subunit selective…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: